|

Colon Cancer Liquid Biopsy Investigation of Methylation-based Biomarkers Evaluation Using Delta-HLD (CLIMBED)

RECRUITINGSponsored by Epiliquid Holding, Inc
Actively Recruiting
SponsorEpiliquid Holding, Inc
Started2024-04-04
Est. completion2025-12
Eligibility
Age45 Years – 75 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07168876

Summary

CLIMBED (Colon cancer Liquid biopsy Investigation of Methylation-based Biomarkers Evaluation using Delta-HLD) is a non-randomized, observational, cross-sectional clinical validation study designed to assess the performance of Delta-HLD, Epiliquid's proprietary liquid biopsy technology, for colorectal cancer (CRC) detection. The study will evaluate the test performance in an average-risk population for CRC undergoing screening colonoscopy, which will serve as the gold standard reference.

Eligibility

Age: 45 Years – 75 YearsHealthy volunteers accepted
Inclusion Criteria:

* Men and women aged 45-75 years
* Indication of colorectal cancer screening colonoscopy by treating physician

Exclusion Criteria:

* First-degree family history of CRC
* Inflammatory bowel disease (ulcerative colitis, Crohn's disease)
* Other malignancies within 5 years
* Known hereditary CRC syndromes (Lynch, FAP)
* Major trauma, surgery, transfusion in past 30 days
* Current participation in an interventional clinical trial

Conditions2

CancerColorectal Cancer (CRC)

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.